<DOC>
	<DOCNO>NCT00254293</DOCNO>
	<brief_summary>The purpose study study serum level Abatacept subcutaneous dose subject RA .</brief_summary>
	<brief_title>Study Assess Steady-State Trough Concentrations , Safety , Immunogenicity Abatacept After Subcutaneous ( SC ) Administration Subjects With Rheumatoid Arthritis ( RA )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Rheumatoid</mesh_term>
	<mesh_term>Pharmaceutical Solutions</mesh_term>
	<mesh_term>Abatacept</mesh_term>
	<criteria>Meet ARA criterion diagnosis RA active disease . RA diagnosis least 1 year . &gt; = 6 swollen joint . &gt; = 8 tender joint . Taking methotrexate ( MTX ) MTX plus 1 added oral DMARD &gt; = 3 month stable 28 day prior dose . Serious acute bacterial infection last 3 month . Chronic recurrent bacterial infection . History TB within previous 3 year old TB adequately treat . Specific lab test abnormality History cancer within 5 year . Exposure CTLA4Ig ( Cytotoxic Tlymphocyte ( Tcell ) associate antigen 4Ig ) , belatacept , rituximab , efalizumab , alefacept , investigational drug biologic . Treatment hydroxychloroquine , azathioprine , leflunomide , immunoadsorption column , mycophenolate mofetil , cyclosporine , DPenicillamine calcineurin inhibitor . Exposure live vaccine .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
</DOC>